LendingTree, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LendingTree, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $900.22M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $672.50M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $984.99M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $1.10B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $909.99M | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | $255.19M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $310.61M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $278.42M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $262.39M | Feb 27, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $352.05M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $309.57M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $289.75M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $368.94M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $410.37M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $369.47M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $432.32M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $305.14M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $251.39M | Feb 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.31M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($41.70M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | ($122.40M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($187.95M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $69.12M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($48.26M) | Feb 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.81M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $44.63M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | ($40.61M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($32.76M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $8.03M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($6.60M) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | $9.02M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $31.19M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $12.32M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | ($1.80M) | Feb 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.25M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $46.36M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $47.20M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $55.55M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $52.87M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $43.64M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $39.95M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $26.96M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $17.93M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $13.76M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.10M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $62.26M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $67.57M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $42.97M | Mar 7, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $855.69M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $767.67M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $802.76M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $1.20B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.30B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.19B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $947.97M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $896.12M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $693.46M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $323.43M | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $568.90M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $658.85M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $678.63M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $991.37M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $851.36M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $824.23M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $545.64M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $549.91M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $398.59M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $91.99M | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $286.80M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $108.82M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $124.13M | Mar 9, 2026 |
| FY2025 | Dec 31, 2022 | $207.94M | Mar 9, 2026 |
| FY2024 | Dec 31, 2021 | $447.99M | Mar 7, 2025 |
| FY2023 | Dec 31, 2020 | $364.76M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $402.33M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $346.21M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $294.87M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $231.44M | Feb 27, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $381.54M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $381.54M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $381.54M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $420.14M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $420.14M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $420.14M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $420.14M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $348.35M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $113.37M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $56.46M | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($728.10M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($879.41M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($837.70M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($715.30M) | Feb 29, 2024 |
| FY2024 | Jan 1, 2022 | ($527.35M) | Mar 7, 2025 |
| FY2024 | Dec 31, 2021 | ($571.79M) | Mar 7, 2025 |
| FY2021 | Dec 31, 2020 | ($640.91M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($592.65M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($610.48M) | Feb 27, 2020 |
| FY2019 | Jan 1, 2018 | ($706.98M) | Feb 27, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.07M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $106.59M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $112.05M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $298.85M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $251.23M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $169.93M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $60.24M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $105.10M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $368.55M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $91.13M | Feb 26, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | (9) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | (14) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 27, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | (9) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | (14) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 27, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.77M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 13.39M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 13.04M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | 12.81M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 13.10M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 13.12M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 13.04M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 12.81M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 11.98M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 11.79M | Feb 26, 2018 |